GRITSTONE BIO INC (GRTS)

US39868T1051 - Common Stock

0.0322  -0.01 (-31.78%)

After market: 0.026 -0.01 (-19.25%)

Fundamental Rating

2

GRTS gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. GRTS may be in some trouble as it scores bad on both profitability and health. GRTS shows excellent growth, but is valued quite expensive already.



Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year GRTS has reported negative net income.
GRTS had a negative operating cash flow in the past year.
GRTS had negative earnings in each of the past 5 years.
In the past 5 years GRTS always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of GRTS (-93.33%) is worse than 75.31% of its industry peers.
With a Return On Equity value of -599.53%, GRTS is not doing good in the industry: 80.64% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -93.33%
ROE -599.53%
ROIC N/A
ROA(3y)-51.54%
ROA(5y)-50.67%
ROE(3y)-123.97%
ROE(5y)-101.08%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GRTS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

More info and screens

2

2. Health

2.1 Basic Checks

GRTS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GRTS has been increased compared to 1 year ago.
The number of shares outstanding for GRTS has been increased compared to 5 years ago.
GRTS has a worse debt/assets ratio than last year.

2.2 Solvency

GRTS has an Altman-Z score of -9.83. This is a bad value and indicates that GRTS is not financially healthy and even has some risk of bankruptcy.
GRTS has a Altman-Z score of -9.83. This is in the lower half of the industry: GRTS underperforms 75.67% of its industry peers.
A Debt/Equity ratio of 1.83 is on the high side and indicates that GRTS has dependencies on debt financing.
GRTS has a Debt to Equity ratio of 1.83. This is amonst the worse of the industry: GRTS underperforms 81.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Altman-Z -9.83
ROIC/WACCN/A
WACC7.5%

2.3 Liquidity

GRTS has a Current Ratio of 2.54. This indicates that GRTS is financially healthy and has no problem in meeting its short term obligations.
With a Current ratio value of 2.54, GRTS is not doing good in the industry: 71.58% of the companies in the same industry are doing better.
A Quick Ratio of 2.54 indicates that GRTS has no problem at all paying its short term obligations.
GRTS has a worse Quick ratio (2.54) than 70.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.54
Quick Ratio 2.54

More info and screens

7

3. Growth

3.1 Past

GRTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.49%, which is quite good.
The Revenue has grown by 25.14% in the past year. This is a very strong growth!
The Revenue has been growing by 68.87% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
Revenue 1Y (TTM)25.14%
Revenue growth 3Y59.34%
Revenue growth 5Y68.87%
Sales Q2Q%-52.89%

3.2 Future

GRTS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.58% yearly.
Based on estimates for the next years, GRTS will show a very strong growth in Revenue. The Revenue will grow by 74.91% on average per year.
EPS Next Y19.29%
EPS Next 2Y8.07%
EPS Next 3Y1.48%
EPS Next 5Y16.58%
Revenue Next Year-74.34%
Revenue Next 2Y-41.42%
Revenue Next 3Y2.57%
Revenue Next 5Y74.91%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GRTS. In the last year negative earnings were reported.
Also next year GRTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.07%
EPS Next 3Y1.48%

More info and screens

0

5. Dividend

5.1 Amount

GRTS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GRITSTONE BIO INC

NASDAQ:GRTS (10/21/2024, 8:17:44 PM)

After market: 0.026 -0.01 (-19.25%)

0.0322

-0.01 (-31.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2024-08-13/amc
Earnings (Next)11-07 2024-11-07/amc
Inst Owners30.17%
Inst Owner Change-8.58%
Ins Owners7.44%
Ins Owner Change-0.14%
Market Cap3.80M
Analysts43.33
Price Target0.77 (2291.3%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)19.93%
Min EPS beat(2)-4.7%
Max EPS beat(2)44.55%
EPS beat(4)3
Avg EPS beat(4)16.23%
Min EPS beat(4)-4.7%
Max EPS beat(4)44.55%
EPS beat(8)7
Avg EPS beat(8)14.69%
EPS beat(12)11
Avg EPS beat(12)14.99%
EPS beat(16)13
Avg EPS beat(16)20.82%
Revenue beat(2)1
Avg Revenue beat(2)10.25%
Min Revenue beat(2)-34.21%
Max Revenue beat(2)54.71%
Revenue beat(4)2
Avg Revenue beat(4)25.15%
Min Revenue beat(4)-34.21%
Max Revenue beat(4)99.1%
Revenue beat(8)3
Avg Revenue beat(8)9.85%
Revenue beat(12)7
Avg Revenue beat(12)19.44%
Revenue beat(16)10
Avg Revenue beat(16)29.53%
PT rev (1m)-81.25%
PT rev (3m)-80.43%
EPS NQ rev (1m)-7.41%
EPS NQ rev (3m)20.85%
EPS NY rev (1m)-5.33%
EPS NY rev (3m)11.86%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)-47.38%
Revenue NY rev (3m)-81.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.26
P/FCF N/A
P/OCF N/A
P/B 0.17
P/tB 0.17
EV/EBITDA N/A
EPS(TTM)-1.09
EYN/A
EPS(NY)-1
Fwd EYN/A
FCF(TTM)-0.95
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.12
BVpS0.19
TBVpS0.19
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -93.33%
ROE -599.53%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-51.54%
ROA(5y)-50.67%
ROE(3y)-123.97%
ROE(5y)-101.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 1.83
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 20.16%
Cap/Sales 9.97%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.54
Quick Ratio 2.54
Altman-Z -9.83
F-Score3
WACC7.5%
ROIC/WACCN/A
Cap/Depr(3y)78.57%
Cap/Depr(5y)125.83%
Cap/Sales(3y)22.91%
Cap/Sales(5y)105.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.49%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%48.39%
EPS Next Y19.29%
EPS Next 2Y8.07%
EPS Next 3Y1.48%
EPS Next 5Y16.58%
Revenue 1Y (TTM)25.14%
Revenue growth 3Y59.34%
Revenue growth 5Y68.87%
Sales Q2Q%-52.89%
Revenue Next Year-74.34%
Revenue Next 2Y-41.42%
Revenue Next 3Y2.57%
Revenue Next 5Y74.91%
EBIT growth 1Y-3.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year11.16%
EBIT Next 3Y-2.82%
EBIT Next 5YN/A
FCF growth 1Y-7.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-12.73%
OCF growth 3YN/A
OCF growth 5YN/A